+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Circulating Tumor Cell Market - Global Forecast 2026-2032- Product Image
Circulating Tumor Cell Market - Global Forecast 2026-2032- Product Image
Sale

Circulating Tumor Cell Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5311178
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Circulating Tumor Cell Market is projected to reach USD 15.52 Billion in 2026. It is expected to continue growing at a CAGR of 10.58%, reaching USD 28.52 Billion by 2032.

The circulating tumor cell (CTC) market sits at the intersection of oncology diagnostics, liquid biopsy, precision medicine, and real-time treatment monitoring. CTCs are rare cancer cells shed from primary or metastatic tumors into the bloodstream, enabling minimally invasive insight into tumor biology without repeated tissue biopsies.

Demand is supported by the global cancer burden. The International Agency for Research on Cancer reported about 20.0 million new cancer cases and 9.7 million cancer deaths in 2022, with new cancer cases projected to exceed 35 million by 2050. Against this backdrop, CTC enrichment, detection, enumeration, and molecular characterization are gaining strategic importance in metastatic disease management, companion diagnostics research, minimal residual disease exploration, and oncology drug development.

Transformative Shifts in the CTC Landscape

The CTC landscape is shifting from cell counting toward deeper biological profiling. Early commercial adoption was anchored by the FDA-cleared CellSearch system for CTC enumeration in metastatic breast, prostate, and colorectal cancers, establishing clinical relevance for standardized CTC measurement.

Today, innovation is moving toward label-free microfluidics, immunomagnetic enrichment, size-based isolation, single-cell sequencing, multi-omics, and combined CTC-circulating tumor DNA workflows. Pharmaceutical sponsors and academic cancer centers are also using CTC assays to support patient stratification, pharmacodynamic monitoring, treatment response assessment, and resistance mechanism discovery in oncology clinical trials.

Cumulative Impact of Artificial Intelligence on CTC Analysis

Artificial intelligence is accelerating CTC analysis by improving image recognition, rare-cell classification, signal interpretation, and workflow automation. AI-enabled pathology and computer vision tools can support more consistent identification of CTC morphology, CTC clusters, apoptotic cells, and epithelial-to-mesenchymal transition phenotypes across large image datasets.

The cumulative impact is strongest when AI is paired with validated sample preparation, reproducible staining, clinically annotated datasets, and transparent performance monitoring. Industry leaders are prioritizing explainable algorithms, bias testing, audit trails, cybersecurity, and regulatory-grade evidence because CTC applications influence high-stakes oncology decisions, including prognosis, treatment response assessment, resistance detection, and trial eligibility.

Key Regional Insights for CTC Adoption

North America leads CTC commercialization through strong oncology research funding, CLIA-certified laboratory infrastructure, FDA device pathways, and broad participation in precision oncology trials. Europe benefits from advanced cancer centers, national screening and research networks, and the EU In Vitro Diagnostic Regulation, which is raising evidence expectations for diagnostic performance, analytical validity, and clinical validity. Asia-Pacific is expanding rapidly as China, Japan, India, South Korea, and Australia invest in cancer diagnostics, hospital modernization, genomic medicine, and translational oncology.

Latin America shows growing demand in Brazil and Mexico as private oncology networks, reference laboratories, and regional clinical research programs adopt liquid biopsy services. The Middle East, led by GCC health systems, is investing in precision medicine, tertiary oncology centers, and digital health infrastructure that can support advanced CTC workflows. Africa remains earlier stage but has long-term need due to increasing cancer incidence, late-stage diagnosis in many countries, and limited tissue biopsy access in resource-constrained settings, making minimally invasive cancer monitoring an important future priority.

Key Group Insights Across Global CTC Markets

The European Union is shaping CTC market quality through IVDR compliance, multicenter validation, clinical evidence requirements, and data protection standards that influence global diagnostic developers. The G7 markets remain central to premium oncology technology adoption because of mature reimbursement systems, research hospitals, advanced laboratory networks, and high pharmaceutical clinical trial density. NATO member countries overlap significantly with high-income healthcare systems that support advanced diagnostics, secure health data exchange, and biosecurity-grade governance for clinical information.

BRICS countries are important volume-growth markets, with China and India driving local manufacturing, cancer center expansion, and cost-sensitive innovation, while Brazil, Russia, and South Africa contribute regional oncology infrastructure and research capacity. ASEAN is gaining relevance through Singapore-led translational research, expanding medical tourism, and rising private cancer care across Southeast Asia. GCC countries are accelerating precision oncology procurement through national health transformation programs, specialized cancer centers, and investments in genomics, laboratory automation, and digital patient pathways.

Key Country Insights in Circulating Tumor Cell Diagnostics

The United States remains the most influential CTC market due to FDA-cleared precedent, venture-backed diagnostics, major cancer centers, CLIA laboratory capacity, and strong oncology trial activity. Canada supports adoption through academic cancer networks and coordinated public health research, while Mexico and Brazil are emerging Latin American anchors for private-sector liquid biopsy testing, oncology specialty care, and regional clinical research.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong oncology care with tightening diagnostic evidence standards, national cancer strategies, and growing use of precision medicine pathways, while Russia presents a more constrained but scientifically capable market with established biomedical research capacity. China is scaling domestic CTC platforms and hospital-based precision oncology; India is prioritizing affordable access and high-throughput diagnostics; Japan emphasizes high-quality oncology testing and regulated clinical translation; South Korea integrates diagnostics with advanced digital health and biotechnology capabilities; and Australia offers a well-regulated environment for translational oncology adoption through academic hospitals and cancer research networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical validation in tumor types where CTCs have demonstrated prognostic or monitoring value, especially metastatic breast, prostate, and colorectal cancers. Product roadmaps should connect CTC enumeration with molecular profiling, therapy resistance analysis, CTC cluster assessment, and longitudinal monitoring to strengthen clinical utility.

Commercial teams should build evidence packages that satisfy regulators, payers, oncologists, and laboratory directors. Recommended actions include multicenter reproducibility studies, standardized pre-analytical protocols, AI model validation, interoperability with electronic health records, partnerships with pharmaceutical sponsors, and region-specific reimbursement strategies that clearly demonstrate how CTC testing changes patient management.

Research Methodology

This executive summary is based on secondary research from authoritative public sources, including international cancer statistics, regulatory databases, peer-reviewed oncology literature, clinical trial registries, health technology assessment references, and public regulatory guidance. Emphasis was placed on verifiable evidence related to CTC technologies, liquid biopsy adoption, oncology diagnostics regulation, regional healthcare infrastructure, and precision medicine implementation.

The methodology applies triangulation across clinical, regulatory, commercial, and technology indicators. Insights were reviewed for consistency with known FDA-cleared CTC use cases, IARC cancer burden data, EU IVDR requirements, clinical evidence on metastatic cancer monitoring, and observed adoption patterns in oncology research, diagnostic laboratories, academic hospitals, and precision medicine programs.

Conclusion

Circulating tumor cell technologies are becoming increasingly relevant as oncology moves toward minimally invasive, longitudinal, and biologically informative diagnostics. CTC analysis offers a distinct advantage because it can provide intact-cell information that complements circulating tumor DNA and tissue biopsy results.

The strongest opportunities will favor organizations that combine analytical rigor, AI-enabled efficiency, clinical evidence, and scalable laboratory workflows. As cancer incidence rises globally, CTC solutions that prove measurable value in treatment monitoring, resistance detection, prognosis, and clinical trial optimization are positioned to gain sustained market relevance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Circulating Tumor Cell Market, by Product Type
7.1. Introduction
7.2. Instruments
7.2.1. CTC Enrichment Systems
7.2.2. CTC Detection Systems
7.2.3. Imaging Systems
7.3. Kits & Reagents
7.3.1. Antibodies & Immunoassay Kits
7.3.2. Staining Reagents
7.3.3. Molecular Assay Kits
7.3.4. PCR Kits
7.4. Blood Collection Tubes
7.5. Consumables
7.5.1. Microfilters
7.5.2. Chips & Cartridges
7.5.3. Slides & Plates
8. Circulating Tumor Cell Market, by Technology Type
8.1. Introduction
8.2. CTC Detection & Enrichment Methods
8.2.1. Immunoaffinity-based Enrichment
8.2.2. Physical Property-based Enrichment
8.2.3. Microfluidics-based Enrichment
8.3. CTC Direct Detection Methods
8.3.1. Imagin- based Detection
8.3.2. Flow Cytometry
8.4. CTC Analysis
8.4.1. Molecular Analysis
8.4.2. Protein Analysis
8.4.3. Functional Assays
9. Circulating Tumor Cell Market, by Specimen
9.1. Introduction
9.2. Blood
9.2.1. Whole Blood
9.2.2. Peripheral Blood
9.3. Bone marrow
10. Circulating Tumor Cell Market, by Application
10.1. Introduction
10.2. Clinical Diagnostics & Research
10.2.1. Cancer Diagnosis
10.2.2. Cancer Prognosis
10.2.3. Therapy Monitoring
10.2.4. Tumorigenesis Research
10.2.5. Cancer Stem Cell Research
10.3. Drug & Therapy Development
10.3.1. Drug Screening
10.3.2. Target Identification
10.3.3. Clinical Trials Support
11. Circulating Tumor Cell Market, by End Users
11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Hospitals & Clinics
11.4. Research & Academic Institutes
11.5. Pharmaceutical & Biotechnology Companies
11.6. Contract Research Organizations
12. Circulating Tumor Cell Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Circulating Tumor Cell Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Circulating Tumor Cell Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Actorius Innovations and Research Pvt Ltd
16.2. Advanced Cell Diagnostics, Inc.
16.3. Bio-Techne Corporation
16.4. BioFluidica
16.5. Biolidics Limited
16.6. Cell Microsystems
16.7. Creatv MicroTech, Inc.
16.8. Greiner Bio-One International GmbH
16.9. Ikonisys, Inc.
16.10. LungLife AI, Inc.
16.11. Menarini Silicon Biosystems
16.12. Miltenyi Biotec GmbH
16.13. Precision Medicine Group, LLC
16.14. QIAGEN N.V.
16.15. Rarecells Diagnostics
16.16. Sartorius AG
16.17. ScreenCell
16.18. SRI International
16.19. STEMCELL Technologies, Inc.
16.20. Sysmex Corporation
16.21. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL CIRCULATING TUMOR CELL MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CIRCULATING TUMOR CELL MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CIRCULATING TUMOR CELL MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CIRCULATING TUMOR CELL MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CIRCULATING TUMOR CELL MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL CIRCULATING TUMOR CELL MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CIRCULATING TUMOR CELL MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CTC ENRICHMENT SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CTC ENRICHMENT SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CTC ENRICHMENT SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CTC DETECTION SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CTC DETECTION SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CTC DETECTION SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL KITS & REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL KITS & REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL KITS & REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIBODIES & IMMUNOASSAY KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIBODIES & IMMUNOASSAY KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIBODIES & IMMUNOASSAY KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL STAINING REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL STAINING REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL STAINING REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MOLECULAR ASSAY KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MOLECULAR ASSAY KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MOLECULAR ASSAY KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PCR KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PCR KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PCR KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BLOOD COLLECTION TUBES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL BLOOD COLLECTION TUBES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL BLOOD COLLECTION TUBES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MICROFILTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MICROFILTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MICROFILTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CHIPS & CARTRIDGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CHIPS & CARTRIDGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CHIPS & CARTRIDGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SLIDES & PLATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SLIDES & PLATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SLIDES & PLATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CTC DETECTION & ENRICHMENT METHODS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CTC DETECTION & ENRICHMENT METHODS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CTC DETECTION & ENRICHMENT METHODS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNOAFFINITY-BASED ENRICHMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNOAFFINITY-BASED ENRICHMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNOAFFINITY-BASED ENRICHMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PHYSICAL PROPERTY-BASED ENRICHMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PHYSICAL PROPERTY-BASED ENRICHMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PHYSICAL PROPERTY-BASED ENRICHMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MICROFLUIDICS-BASED ENRICHMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MICROFLUIDICS-BASED ENRICHMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MICROFLUIDICS-BASED ENRICHMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CTC DIRECT DETECTION METHODS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CTC DIRECT DETECTION METHODS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CTC DIRECT DETECTION METHODS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL IMAGIN- BASED DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL IMAGIN- BASED DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL IMAGIN- BASED DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CTC ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CTC ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CTC ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL MOLECULAR ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL MOLECULAR ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MOLECULAR ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PROTEIN ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PROTEIN ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PROTEIN ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL FUNCTIONAL ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL FUNCTIONAL ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL FUNCTIONAL ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL CLINICAL DIAGNOSTICS & RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL CLINICAL DIAGNOSTICS & RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CLINICAL DIAGNOSTICS & RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL CANCER DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL CANCER DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL CANCER PROGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL CANCER PROGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL CANCER PROGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL THERAPY MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL THERAPY MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL THERAPY MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL TUMORIGENESIS RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL TUMORIGENESIS RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL TUMORIGENESIS RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL CANCER STEM CELL RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL CANCER STEM CELL RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL CANCER STEM CELL RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL DRUG & THERAPY DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL DRUG & THERAPY DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL DRUG & THERAPY DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 186. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 188. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 189. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 190. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 191. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 192. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 193. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 194. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 195. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 196. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 197. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 198. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 199. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 200. EUROPE CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 216. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 217. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 218. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 219. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 220. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 221. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 222. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 223. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 224. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 225. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 226. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 227. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 229. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 230. AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 231. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 232. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 233. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 234. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 235. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 236. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 237. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 238. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 239. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 240. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 241. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 242. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 243. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 245. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 246. ASEAN CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 247. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 248. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 249. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 250. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 251. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 252. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 253. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 254. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 255. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 256. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 257. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 258. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 260. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 261. GCC CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 277. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 278. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 279. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 280. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 281. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 282. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 283. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 284. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 285. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 286. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 287. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 288. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 289. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 290. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 291. BRICS CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 292. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 293. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 294. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 295. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 296. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 297. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 298. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 299. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 300. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 301. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 302. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 303. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 304. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 305. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 306. G7 CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 307. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 308. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 309. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 310. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 311. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 312. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 313. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 314. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 315. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 316. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 317. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 318. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 319. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 320. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 321. NATO CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 322. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 334. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 335. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, 2017-2032 (USD MILLION)
TABLE 336. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG & THERAPY DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 337. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 338. CANADA CIRCULATING TUMOR CELL MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 339. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 340. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 341. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, 2017-2032 (USD MILLION)
TABLE 342. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 343. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 344. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2017-2032 (USD MILLION)
TABLE 345. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2017-2032 (USD MILLION)
TABLE 346. CANADA CIRCULATING TUMOR CEL

Companies Mentioned

  • Actorius Innovations and Research Pvt Ltd
  • Advanced Cell Diagnostics, Inc.
  • Bio-Techne Corporation
  • BioFluidica
  • Biolidics Limited
  • Cell Microsystems
  • Creatv MicroTech, Inc.
  • Greiner Bio-One International GmbH
  • Ikonisys, Inc.
  • LungLife AI, Inc.
  • Menarini Silicon Biosystems
  • Miltenyi Biotec GmbH
  • Precision Medicine Group, LLC
  • QIAGEN N.V.
  • Rarecells Diagnostics
  • Sartorius AG
  • ScreenCell
  • SRI International
  • STEMCELL Technologies, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 15.52 Billion
Forecasted Market Value ( USD ) by 2032 $ 28.52 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Circulating Tumor Cells Market Report by Technology, Application, Product, Specimen, End User, and Region 2026-2034 - Product Image

Circulating Tumor Cells Market Report by Technology, Application, Product, Specimen, End User, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From
Circulating Tumor Cells Market Size, Share & Trends Analysis Report by Application (Clinical, Research), Specimen (Bone Marrow, Blood), Product (Kits & Reagents, Blood Collection Tubes), Technology, End Use, and Region with Growth Forecasts, 2026-2033 - Product Image

Circulating Tumor Cells Market Size, Share & Trends Analysis Report by Application (Clinical, Research), Specimen (Bone Marrow, Blood), Product (Kits & Reagents, Blood Collection Tubes), Technology, End Use, and Region with Growth Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
Circulating Tumor Cells (CTC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Circulating Tumor Cells (CTC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 112 Pages
  • Global
From
Circulating Tumor Cells Global Market Insights 2026, Analysis and Forecast to 2031 - Product Image

Circulating Tumor Cells Global Market Insights 2026, Analysis and Forecast to 2031

  • Report
  • 89 Pages
  • Global
From
Circulating Tumor Cells Market Report 2026 - Product Image

Circulating Tumor Cells Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Circulating Tumor Cell Market

Circulating Tumor Cells (CTCs) are a type of biomarker used to detect and monitor cancer. CTCs are cells that have been shed from a tumor and are present in the bloodstream. They can be used to diagnose cancer, monitor its progression, and assess the effectiveness of treatments. CTCs are also used to identify new therapeutic targets and to develop personalized treatments. CTCs are a rapidly growing market, with a range of products and services available to researchers and clinicians. Companies in the CTC market offer technologies for isolating, analyzing, and characterizing CTCs, as well as services for CTC-based diagnostics and drug development. Examples of companies in the CTC market include ApoCell, Menarini Silicon Biosystems, and RareCyte. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.